Preeclampsia Diagnostics Market Growth Projections and Trends


Preeclampsia, a pregnancy complication characterized by high blood pressure and signs of damage to other organ systems, most often the liver and kidneys, poses significant risks to both the mother and the fetus. Early and accurate diagnosis of preeclampsia is critical for effective management and improved outcomes. The global preeclampsia diagnostics market size was valued at USD 1.08 billion in 2023 and is expected to reach USD 1.33 billion by 2031, growing at a compound annual growth rate (CAGR) of 2.7% from 2024 to 2031. This article delves into the key drivers, market segmentation, regional analysis, competitive landscape, and future outlook of the preeclampsia diagnostics market.

Market Drivers

Rising Prevalence of Preeclampsia

The increasing incidence of preeclampsia, particularly in developed countries, is a significant driver of market growth. Factors such as advanced maternal age, obesity, and pre-existing health conditions contribute to the rising prevalence. As awareness about the condition grows, so does the demand for effective diagnostic solutions.

Advancements in Diagnostic Technologies

Technological advancements in diagnostic methods have significantly improved the accuracy and efficiency of preeclampsia detection. Innovations such as biomarker-based tests, point-of-care testing, and advanced imaging techniques are enhancing early diagnosis and monitoring, leading to better management of the condition.

Increasing Awareness and Healthcare Expenditure

Rising awareness about maternal health and the importance of early detection of pregnancy-related complications are boosting the demand for preeclampsia diagnostics. Additionally, increasing healthcare expenditure and government initiatives aimed at improving maternal health are further propelling market growth.

Download Free Sample Report of Preeclampsia Diagnostics Market @ 

Market Segmentation

By Test Type

The preeclampsia diagnostics market can be segmented based on test types into blood tests, urine tests, imaging tests, and others.

  • Blood Tests: Blood tests are commonly used to measure levels of specific biomarkers, such as proteinuria and platelet count, which are indicative of preeclampsia. These tests are widely adopted due to their high accuracy and reliability.
  • Urine Tests: Urine tests are used to detect protein levels, which is a key indicator of preeclampsia. They are simple, non-invasive, and cost-effective, making them a popular choice in clinical settings.
  • Imaging Tests: Imaging tests, such as ultrasound and Doppler scans, are used to monitor the health of the fetus and placenta, providing valuable information for the diagnosis and management of preeclampsia.
  • Others: Other diagnostic methods include non-invasive tests and point-of-care devices that offer rapid and accurate results, enhancing early detection and intervention.

By End-User

The market is segmented by end-users into hospitals, diagnostic laboratories, specialty clinics, and others.

  • Hospitals: Hospitals hold the largest market share due to the high volume of pregnancy-related consultations and the availability of advanced diagnostic equipment.
  • Diagnostic Laboratories: Diagnostic laboratories are critical for conducting specialized tests and analyses, contributing significantly to the market.
  • Specialty Clinics: Specialty clinics focusing on maternal and fetal health are increasingly adopting advanced diagnostic tools, driving market growth.
  • Others: Other end-users include research institutions and home care settings, where portable and easy-to-use diagnostic devices are gaining popularity.

Regional Analysis

North America

North America dominates the preeclampsia diagnostics market, attributed to advanced healthcare infrastructure, high awareness levels, and significant investments in research and development. The United States is the major contributor to the regional market, with numerous healthcare facilities and diagnostic laboratories offering advanced testing options.


Europe is the second-largest market for preeclampsia diagnostics, driven by robust healthcare systems, favorable government policies, and increasing awareness about maternal health. Countries such as Germany, the United Kingdom, and France are leading the market due to their proactive adoption of advanced diagnostic technologies.


The Asia-Pacific region is poised for substantial growth during the forecast period, driven by rising healthcare expenditure, improving healthcare infrastructure, and increasing awareness about preeclampsia. Countries such as China, India, and Japan are expected to be major contributors to the regional market growth.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa regions are also witnessing steady growth in the preeclampsia diagnostics market. Improving access to healthcare services, growing awareness about maternal health, and increasing investments in healthcare infrastructure are key factors driving market growth in these regions.

Competitive Landscape

The preeclampsia diagnostics market is moderately competitive, with several key players actively engaged in research, development, and commercialization of innovative diagnostic solutions. Prominent companies include:

  • Thermo Fisher Scientific: A leader in providing advanced diagnostic solutions, including biomarker-based tests for preeclampsia.
  • PerkinElmer, Inc.: Known for its expertise in prenatal screening and diagnostics, offering a range of tests for early detection of preeclampsia.
  • F. Hoffmann-La Roche Ltd: A major player in the diagnostics market, providing comprehensive solutions for maternal and fetal health.
  • Siemens Healthineers: Focused on offering advanced imaging and diagnostic technologies for early detection and management of preeclampsia.
  • GE Healthcare: A key player in the market, providing innovative imaging solutions and diagnostic tools for maternal health.

These companies are focusing on strategic collaborations, mergers and acquisitions, and product launches to strengthen their market position and expand their product portfolios.

Future Outlook

The future of the preeclampsia diagnostics market looks promising, with several factors expected to drive its growth. Continued advancements in diagnostic technologies, increasing prevalence of preeclampsia, and rising awareness about maternal health are anticipated to propel the market forward. Additionally, the growing trend of personalized medicine and the integration of artificial intelligence (AI) in diagnostics are likely to create new opportunities for market expansion. Companies operating in this space will need to stay at the forefront of innovation and adapt to changing market dynamics to maintain their competitive edge.


The preeclampsia diagnostics market is experiencing steady growth, driven by a combination of factors including advancements in diagnostic technologies, increasing prevalence of preeclampsia, and rising awareness about maternal health. With a projected market size of USD 1.33 billion by 2031, the sector offers significant opportunities for companies and investors alike. As the healthcare industry continues to prioritize maternal and fetal health, the adoption of innovative diagnostic solutions is expected to soar, paving the way for improved outcomes and better management of preeclampsia.

Check Out More Research Studies

Regenerative Medicine Market Size

Precision Diagnostics Market Size

Botulinum Toxin Market Size

Medical Imaging Market Size

Spirometer Market Size